Mucosal vaccination against bacterial respiratory infections.
Mucosal vaccination offers attractive advantages to conventional systemic vaccination, such as higher levels of antibodies and protection at the airway surface. This review gives an overview of recent experimental and clinical data on nasal, oral and sublingual vaccines against bacterial respiratory pathogens, such as Streptococcus pneumoniae , Haemophilus influenzae , Neisseria meningitidis , Moraxella catarrhalis , Bordetella pertussis , Pseudomonas aeruginosa and Mycobacterium tuberculosis . Subsequently, we discuss further vaccine development that opens the focus to clinical use.
Baumann
Ulrich
U
Immunological Unit, Department of Pediatric Pulmonology and Neonatology, Hanover Medical School, Carl-Neuberg-Str., 30625 Hannover, Germany. baumann.ulrich@mh-hannover.de
D000281:Administration, Intranasal; D000284:Administration, Oral; D000286:Administration, Sublingual; D001424:Bacterial Infections / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D020545:Respiratory Mucosa / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000517:prevention & control*
D001428:Bacterial Vaccines